Latest news

• Positive mid-stage trial gives Allergy’s investors some welcome relief

  All of the doses were safe and well-tolerated in the 447-patient study, according to Allergy, which was hit hard 11 years ago when the FDA placed its Pollinex Quattro

• Leaning forward

  The company's flagship product is Pollinex Quattro, which is transforming immunotherapy by vaccinating against allergy with only four injections. ... A more structured process for classifying and resolving incidents.  . Pollinex Quattro allergy vaccine.

• Yo-yoing

  R204, which marks an important step in the development of Pollinex Quattro for ragweed allergy.

• Time for a tumble

  progress made in clinical trials, particularly that of lead product, Pollinex Quattro, a four-shot vaccination for allergy sufferers.

• Hitting the highs and lows

  Allergy Therapeutics makes a hayfever vaccine Pollinex Quattro in Europe on a 'named patient basis'. ... Pollinex Quattro improves on this as the treatment is delivered in just four injections.